It’s not your father’s transcatheter aortic valve implant anymore.
Next year and the year after, the competitive landscape for TAVI will explode, with as many as 12 competing devices on the market here and across the pond.
And that competition will be fierce. As TAVI celebrates its 10th birthday,at least 1 analyst is predicting a 20%+ compound annual growth rate for the market, which she says could potentially double by 2015.
The FDA approved a surgical gel designed to temporarily stop blood flow during procedures.
The water-soluble, low-viscosity gel designed by Woburn, Mass.-based Pluromed forms a plug at body temperature to temporarily stent blood vessels without damaging them.
FOR IMMEDIATE RELEASE
US Media/Investor Contact:
Ronald Trahan, APR, Ronald Trahan Associates, +1-508-359-4005, x108
JenaValve is first in receiving CE certification for a true second generation transapical TAVI system
Results of the pivotal CE-mark trial of the JenaValve transapical TAVI system are being presented for the first time, on October 3rd, at the 25th Annual Meeting of the European Association for Cardio-Thoracic Surgery (EACTS) in Lisbon
MUNICH, Germany, Sept. 30, 2011 — JenaValve Technology GmbH, a German medical device company specializing in the development of transcatheter heart
Brainsway Ltd.’s (PINK:BRSYF) transcranial magnetic stimulation device won Israeli Ministry of Health approval to treat major depression, bipolar disorder and negative impairment in schizophrenia patients.
The approval clears Jerusalem-based Brainsway to sell the non-invasive TMS device, which delivers brief magnetic pulses to the brain, to four medical centers specializing in mental disorders.
Ball, 55, replaces Hospira founder Christopher Begley, who’s staying on as executive chairman.
Ball spent 16 years at Allergan, rising to president after stints leading its pharmaceuticals , global eye care and North American businesses.